Nonalcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver Disease is a topic covered in the Washington Manual of Medical Therapeutics.
To view the entire topic, please log in or purchase a subscription.
The Washington Manual is an award-winning, complete mobile solution for nurses and students. Look up information on diseases, tests, and procedures; then consult the database with 5,000+ drugs or refer to 65,000+ dictionary terms. Explore these free sample topics:
-- The first section of this topic is shown below --
General Principles
- Nonalcoholic fatty liver disease (NAFLD) is a clinicopathologic syndrome that encompasses several clinical entities that range from simple steatosis to steatohepatitis, fibrosis, ESLD, and HCC in the absence of significant alcohol consumption.
- NASH is part of the spectrum of NAFLD and is defined as the presence of hepatic steatosis and inflammation with hepatocyte injury (ballooning) with or without fibrosis.
- NAFLD is associated with an increasing prevalence of type 2 diabetes, obesity, and the metabolic syndrome in the US population.
- NAFLD has become one of the leading causes of liver transplantation in the US.
-- To view the remaining sections of this topic, please log in or purchase a subscription --
General Principles
- Nonalcoholic fatty liver disease (NAFLD) is a clinicopathologic syndrome that encompasses several clinical entities that range from simple steatosis to steatohepatitis, fibrosis, ESLD, and HCC in the absence of significant alcohol consumption.
- NASH is part of the spectrum of NAFLD and is defined as the presence of hepatic steatosis and inflammation with hepatocyte injury (ballooning) with or without fibrosis.
- NAFLD is associated with an increasing prevalence of type 2 diabetes, obesity, and the metabolic syndrome in the US population.
- NAFLD has become one of the leading causes of liver transplantation in the US.
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Bhat, Pavat, et al., editors. "Nonalcoholic Fatty Liver Disease." Washington Manual of Medical Therapeutics, 35th ed., Wolters Kluwer Health, 2016. The Washington Manual, www.unboundmedicine.com/washingtonmanual/view/Washington-Manual-of-Medical-Therapeutics/602069/all/Nonalcoholic_Fatty_Liver_Disease.
Nonalcoholic Fatty Liver Disease. In: Bhat PP, Dretler AA, Gdowski MM, et al, eds. Washington Manual of Medical Therapeutics. Wolters Kluwer Health; 2016. https://www.unboundmedicine.com/washingtonmanual/view/Washington-Manual-of-Medical-Therapeutics/602069/all/Nonalcoholic_Fatty_Liver_Disease. Accessed April 1, 2023.
Nonalcoholic Fatty Liver Disease. (2016). In Bhat, P., Dretler, A., Gdowski, M., Ramgopal, R., & Williams, D. (Eds.), Washington Manual of Medical Therapeutics (35th ed.). Wolters Kluwer Health. https://www.unboundmedicine.com/washingtonmanual/view/Washington-Manual-of-Medical-Therapeutics/602069/all/Nonalcoholic_Fatty_Liver_Disease
Nonalcoholic Fatty Liver Disease [Internet]. In: Bhat PP, Dretler AA, Gdowski MM, Ramgopal RR, Williams DD, editors. Washington Manual of Medical Therapeutics. Wolters Kluwer Health; 2016. [cited 2023 April 01]. Available from: https://www.unboundmedicine.com/washingtonmanual/view/Washington-Manual-of-Medical-Therapeutics/602069/all/Nonalcoholic_Fatty_Liver_Disease.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Nonalcoholic Fatty Liver Disease
ID - 602069
ED - Williams,Dominique,
ED - Bhat,Pavat,
ED - Dretler,Alexandra,
ED - Gdowski,Mark,
ED - Ramgopal,Rajeev,
BT - Washington Manual of Medical Therapeutics
UR - https://www.unboundmedicine.com/washingtonmanual/view/Washington-Manual-of-Medical-Therapeutics/602069/all/Nonalcoholic_Fatty_Liver_Disease
PB - Wolters Kluwer Health
ET - 35
DB - The Washington Manual
DP - Unbound Medicine
ER -